clinical trial · NCT07217886
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Renal ImpairmentS-892216-PO
brief summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
started
Oct 16, 2025
primary completion
Feb 13, 2026
completion
Feb 13, 2026
last updated
Sep 1, 2026
official title
A Phase 1, Multicenter, Nonrandomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of S-892216-PO in Participants With Varying Degrees of Renal Impairment and Matched Control Participants With Normal Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol